
Opinion|Videos|January 11, 2024
HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer
Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tinostamustine Orphan Drug Designation for Malignant Gliomas
2
Behind the FDA’s Elimination of REMS Program for CAR T-Cell Therapies
3
FDA Fast Tracks Bispecific ADC AVZO-1418 for EGFR-Mutated Pretreated NSCLC
4
First Patient Dosed in SANTANA-225 Trial of ES-SCLC and MCC Therapy
5







































